Inducibility of drug-Metabolizing enzymes by xenobiotics in mice with liver-Specific knockout of ctnnb1

Drug Metabolism and Disposition

Volumn 37, Issue 5, 2009, Pages 1138-1145

  Braeuning, Albert ^a   Sanna, Riccardo ^b   Huelsken, Joerg ^c   Schwarz, Michael ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS(3,5 DICHLORO 2 PYRIDYLOXY)BENZENE; 3 METHYLCHOLANTHRENE; AROMATIC HYDROCARBON RECEPTOR; BETA CATENIN; CELL NUCLEUS RECEPTOR; CLOFIBRATE; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 2E1; DRUG METABOLIZING ENZYME; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHENOBARBITAL; PREGNANE X RECEPTOR; TRANSCRIPTION FACTOR NRF2; WNT PROTEIN; XENOBIOTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CTNNB1 GENE; ENZYME LOCALIZATION; ENZYME REGULATION; FEMALE; GENE; GENE EXPRESSION; IN VIVO STUDY; LIVER CELL; LIVER METABOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; XENOBIOTIC METABOLISM;

ANIMALS; BETA CATENIN; BLOTTING, WESTERN; CYTOCHROME P-450 CYP2E1; ENZYME INDUCTION; FEMALE; HEPATOCYTES; IMMUNOHISTOCHEMISTRY; LIVER; MALE; MICE; MICE, KNOCKOUT; NF-E2-RELATED FACTOR 2; PHARMACEUTICAL PREPARATIONS; PHENOBARBITAL; PYRIDINES; RECEPTORS, ARYL HYDROCARBON; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; XENOBIOTICS;

MAMMALIA; MUS;

EID: 66449102968     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.026179     Document Type: Article

References (30)

1. Bars RG and Elcombe CR (1991) Dose-dependent acinar induction of cytochromes P450 in ratliver. Evidence for a differential mechanism of induction of P450IA1 by beta-naphthoflavoneand dioxin. Biochem J 277 (Pt 2):577-580.
2. Benhamouche S, Decaens T, Godard C, Chambrey R, Rickman DS, Moinard C, Vasseur-CognetM, Kuo CJ, Kahn A, Perret C, et al. (2006) Apc tumor suppressor gene is the "zonation-keeper" of mouse liver. Dev Cell 10:759-770.
3. Bock KW (1994) Aryl hydrocarbon or dioxin receptor: biologic and toxic responses. Rev PhysiolBiochem Pharmacol 125:1-42.
4. Braeuning A, Ittrich C, Kohle C, Buchmann A, and Schwarz M (2007a) Zonal gene expressionin mouse liver resembles expression patterns of Ha-ras and beta-catenin mutated hepatomas.Drug Metab Dispos 35:503-507.
5. Braeuning A, Ittrich C, Kohle C, Hailfinger S, Bonin M, Buchmann A, and Schwarz M (2006)Differential gene expression in periportal and perivenous mouse hepatocytes. FEBS J 273:5051-5061.
6. Braeuning A, Menzel M, Kleinschnitz EM, Harada N, Tamai Y, Kohle C, Buchmann A, and Schwarz M (2007b) Serum components and activated Ha-ras antagonize expression of perivenous marker genes stimulated by beta-catenin signaling in mouse hepatocytes. FEBS J 274:4766-4777.
7. Chesire DR, Dunn TA, Ewing CM, Luo J, and Isaacs WB (2004) Identification of aryl hydrocarbon receptor as a putative Wnt/beta-catenin pathway target gene in prostate cancercells. Cancer Res 64:2523-2533.
8. Foster JR, Elcombe CR, Boobis AR, Davies DS, Sesardic D, McQuade J, Robson RT, HaywardC, and Lock EA (1986) Immunocytochemical localization of cytochrome P-450 in hepatic andextra-hepatic tissues of the rat with a monoclonal antibody against cytochrome P-450 c.Biochem Pharmacol 35:4543-4554.
9. Gebhardt R (1992) Metabolic zonation of the liver: regulation and implications for liver function.Pharmacol Ther 53:275-354.
10. Hailfinger S, Jaworski M, Braeuning A, Buchmann A, and Schwarz M (2006) Zonal geneexpression in murine liver: lessons from tumors. Hepatology 43:407-414.
11. Huelsken J, Vogel R, Erdmann B, Cotsarelis G, and Birchmeier W (2001) beta-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell 105:533-545.
12. Jungermann K and Katz N (1989) Functional specialization of different hepatocyte populations. Physiol Rev 69:708-764.
13. Ledda-Columbano GM, Pibiri M, Concas D, Molotzu F, Simbula G, Cossu C, and Columbano A (2003) Sex difference in the proliferative response of mouse hepatocytes to treatment with the CAR ligand, TCPOBOP. Carcinogenesis 24:1059-1065.
14. Lindros KO (1997) Zonation of cytochrome P450 expression, drug metabolism and toxicity in liver. Gen Pharmacol 28:191-196.
15. Loeppen S, Koehle C, Buchmann A, and Schwarz M (2005) A beta-catenin-dependent pathway regulates expression of cytochrome P450 isoforms in mouse liver tumors. Carcinogenesis 26:239-248.
16. Lustig B and Behrens J (2003) The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 129:199-221.
17. Oinonen T and Lindros KO (1998) Zonation of hepatic cytochrome P-450 expression and regulation. Biochem J 329 (Pt 1):17-35.
18. Oinonen T, Saarikoski S, Husgafvel-Pursiainen K, Hirvonen A, and Lindros KO (1994) Pre- translational induction of cytochrome P4501A enzymes by beta-naphtoflavone and 3-methyl-cholanthrene occurs in different liver zones. Biochem Pharmacol 48:2189-2197.
19. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR.
20. Nucleic Acids Res 29:e45.
21. Saad B, Thomas H, Schawalder H, Waechter F, and Maier P (1994) Oxygen tension, insulin, and glucagon affect the preservation and induction of cytochrome P450 isoforms in cultured rat hepatocytes. Toxicol Appl Pharmacol 126:372-379.
22. Sekine S, Gutierrez PJ, Lan BY, Feng S, and Hebrok M (2007) Liver-specific loss of beta-catenin results in delayed hepatocyte proliferation after partial hepatectomy. Hepatology 45:361-368.
23. Sekine S, Lan BY, Bedolli M, Feng S, and Hebrok M (2006) Liver-specific loss of /3-catenin blocks glutamine synthesis pathway activity and cytochrome P450 expression in mice. Hepatology 43:817-825.
24. Stahl S, Ittrich C, Marx-Stoelting P, Kohle C, Altug-Teber O, Riess O, Bonin M, Jobst J, Kaiser S, Buchmann A, et al. (2005) Genotype-phenotype relationships in hepatocellular tumors from mice and man. Hepatology 42:353-361.
25. Swales K and Negishi M (2004) CAR, driving into the future. Mol Endocrinol 18:1589-1598.
26. Tan X, Behari J, Cieply B, Michalopoulos GK, and Monga SP (2006) Conditional deletion of beta-catenin reveals its role in liver growth and regeneration. Gastroenterology 131:1561-1572.
27. Tritscher AM, Goldstein JA, Portier CJ, McCoy Z, Clark GC, and Lucier GW (1992) Dose-response relationships for chronic exposure to 2,3,7,8- tetrachlorodibenzo-p-dioxin in a rat tumor promotion model: quantification and immunolocalization of CYP1A1 and CYP1A2 in the liver. Cancer Res 52:3436-3442.
28. Wachstein M and Meisel E (1957) Histochemistry of hepatic phosphatases of a physiologic pH;with special reference to the demonstration of bile canaliculi. Am J Clin Pathol 27:13-23.
29. Willert K and Nusse R (1998) Beta-catenin: a key mediator of Wnt signaling. Curr Opin Genet Dev 8:95-102.
30. Wolf CR, Moll E, Friedberg T, Oesch F, Buchmann A, Kuhlmann WD, and Kunz HW (1984)Characterization, localization and regulation of a novel phenobarbital-inducible form of cytochrome P450, compared with three further P450-isoenzymes, NADPH P450-reductase, glutathione transferases and microsomal epoxide hydrolase. Carcinogenesis 5:993-1001.